Nkarta, Inc., a clinical-stage biotech company developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced it will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Nkarta's President Nadir Mahmood will discuss updates on their investigational CAR-NK cell therapy targeting B cell-mediated autoimmune diseases. The presentation will be webcast live and available for replay on Nkarta's website. This event highlights Nkarta's progress in advancing off-the-shelf NK cell therapies designed for outpatient use, potentially broadening patient access to innovative autoimmune treatments in community health settings.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
RMX Industries released Part Three of its series on Real-World Intelligence, focusing on the QuantrusX™ Distributed Data Center (QXDDC). This new brief explains how connected QuantrusX™ nodes share learning across a distributed network, enabling each...
The $110 billion merger between Paramount Skydance and Warner Bros. Discovery closed on October 6, 2026. Warner Bros. Discovery shareholders received $31 per share in cash, exiting with no debt risk. Paramount Skydance shareholders retained shares in...
Lexaria Bioscience highlights the rapid growth of the oral GLP-1 drug market, projected to expand from $5.1 billion in 2026 to $89 billion by 2034. This growth is fueled by patient preference for oral medications over injections and advancements in L...
Silver Bullet Mines Corp. is advancing exploration at its Columbia / Gold Queen Complex in Arizona, discovering new high-grade gold zones and large mineralized stockpiles likely from historic mining. The company plans to assay these stockpiles and co...
